OncLive SOSS

Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC) - Episode 6

Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)

February 3, 2025

Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center, Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC

Panelists discuss the priority next steps for PDS0101 plus pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): expand clinical trials, identify predictive biomarkers, assess long-term safety, and explore additional combination approaches.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Introduction and Incidence of HPV-Positive Head and Neck Cancer

EP. 2: Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors

EP. 3: Navigating Treatment for HPV-Positive HNSCC Patients

EP. 4: Academic Perspectives for the Management of HPV-Positive HNSCC

EP. 5: Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC

EP. 6: Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)

EP. 7: Treatment Insights for R/M HPV-Positive HNSCC

EP. 8: Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Video content above is prompted by the following:

Please discuss the next steps in research for the combination of PDS0101 plus pembrolizumab in R/M HNSCC.
VERSATILE-003

x